undamentalytics Newsletter

Insmed Inc insider trading

Every open-market purchase and sale by Insmed Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Insmed Inc insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Insmed Inc’s insiders pay?

From March 24, 2011 to September 11, 2026, 24 insiders reported 32 open-market purchases and 138 sales not made under a pre-set plan in Insmed Inc. Twelve months after each purchase was reported, the shares were +5.9% against the S&P 500 on average (median −6.8%), over 30 purchases with a full year of prices; 40% beat the index. After sales, the shares moved +33.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 25, 2011 into $47,921 by November 2, 2026, +10.6% a year. It held shares 73% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $59,392 (+12.1% a year), and held throughout $75,574 (+13.9%).

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $75.6k$59.4k$47.9k
Copying Insmed Inc's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Insmed Inc's insiders from March 25, 2011, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 73% of the time.
Insmed Inc: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Lewis William Chair and CEO 7 +70.8% (7) 57% 17 +37.5% (13) June 5, 2026
Smith Michael Alexander Chief Legal Officer 0 — — 20 +57.5% (16) June 5, 2026
Adsett Roger Chief Operating Officer 1 −6.8% (1) 0% 18 +30.6% (13) August 12, 2026
Schaeffer Orlov S Nicole Chief People Strategy Officer 0 — — 18 +28.0% (17) November 14, 2025
Sharoky Melvin Md Director 8 −3.9% (7) 57% 8 −40.0% (6) August 19, 2026
Bonstein Sara Chief Financial Officer 0 — — 14 +53.1% (10) June 5, 2026
Flammer Martina M.D. Chief Medical Officer 0 — — 11 +37.1% (11) June 4, 2025
Fmr LLC 10% owner 0 — — 9 +28.0% (9) July 23, 2013
Wise John Drayton Chief Commercial Officer 0 — — 8 +77.3% (8) February 7, 2025
Engelsen Steinar J Director 4 −34.3% (4) 0% 0 — November 3, 2021
Soriano John Chief Compliance Officer 0 — — 4 −37.9% (4) September 9, 2021
Hayden Donald J Jr Director 2 −52.5% (2) 0% 1 −59.3% (1) September 3, 2015
Pellizzari Christine A Chief Legal Officer 2 +76.4% (2) 100% 1 −35.0% (1) November 5, 2020
Anderson Elizabeth M Director 0 — — 2 — November 26, 2025
Brennan David R Director 1 −27.4% (1) 0% 1 — September 11, 2026
Drechsler Andrew T Chief Financial Officer 0 — — 2 +64.1% (2) March 3, 2017
Lee Leo Director 1 +13.8% (1) 100% 1 — November 18, 2025
Whitcomb Randall W Director 2 −49.9% (2) 0% 0 — March 29, 2011
Whitten Timothy President & CEO 2 −57.3% (1) 0% 0 — June 4, 2012
Desjardins Clarissa Director 1 +26.5% (1) 100% 0 — May 22, 2025
Goll John Chief Accounting Officer 0 — — 1 +70.2% (1) November 20, 2019
Gupta Renu EVP & Chief Medical Officer 1 −50.4% (1) 0% 0 — March 28, 2011
Potter Myrtle S Director 0 — — 1 +101.3% (1) December 15, 2016
Quigley Mark Vice President, Quality 0 — — 1 −51.3% (1) May 13, 2015

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Insmed Inc

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Insmed Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −3.8% against the index. After 9 selling crowds, +27.0%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
January 31, 20253 selling0.0%+39.8%+89.3%
May 31, 20247 selling+31.7%+21.6%+19.4%
January 31, 20247 selling−11.9%+157.8%+154.8%
May 31, 20237 selling+7.7%+22.3%+161.2%
January 31, 20237 selling−12.0%−10.5%+10.3%
May 31, 20226 selling+30.1%−0.3%−1.7%
January 31, 20226 selling+6.6%+1.1%+2.5%
November 30, 20212 buying−10.1%−25.4%−23.7%
September 30, 20203 selling−5.8%−10.3%−44.3%
November 30, 20184 buying+62.6%+29.2%+13.7%
December 30, 20163 selling+25.8%+21.9%+122.8%
March 31, 20114 buying+77.6%−15.1%−54.7%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Insmed Inc · Funds · Politicians